Willie B. Thomas/DigitalVision via Getty Images Investment action I recommended a buy rating for Dexcom (NASDAQ:DXCM) when I wrote about it during October last year, as the 3Q23 results gave me further confidence in the business's positive outlook. The share price has rallied strongly post-my update, back to as high as DXCM’s 1-year all-time high of $142 (~10% below my target price). Based on my current outlook and analysis, I recommend a buy rating. My key update to my thesis is that DXCM should contin ...

Editor's note: Seeking Alpha is proud to welcome Nicholas Sylvia as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » JHVEPhoto I believe that DexCom is undervalued and that a price correction could occur within the next 12 months for the following reasons: Manufacturing Consolidation - I believe DexCom has the ability to s ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

DexCom, Inc. (DXCM) reported first-quarter 2024 adjusted earnings per share (EPS) of 32 cents, which beat the Zacks Consensus Estimate of 27 cents by 18.5%. The company reported earnings of 17 cents per share in the prior-year quarter.DXCM registered GAAP net income per share of 36 cents, up from the year-ago quarter’s figure of 12 cents.Revenue DetailsTotal revenues grew 24% (25% on an organic basis) to $921 million on a year-over-year basis and beat the Zacks Consensus Estimate by 1.1%. Strong revenue gro ...

DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Jeff Johnson - Robert W. Baird Jason Bedford - Raymond James Malgaret Andrew - Willi ...

For the quarter ended March 2024, DexCom (DXCM) reported revenue of $921 million, up 24.2% over the same period last year. EPS came in at $0.32, compared to $0.17 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $911.2 million, representing a surprise of +1.08%. The company delivered an EPS surprise of +18.52%, with the consensus EPS estimate being $0.27.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction ...

• • • • Three Months Ended March 31, Three Months Ended March 31, (In millions) 2024 2023 (In millions, except per share data) 2024 2023 GAAP gross profit $ 561.9 $ 462.6 GAAP net income $ 146.4 $ 48.6 Amortization of intangible assets (1) 7.2 7.2 Amortization of intangible assets (1) 10.4 9.0 Non-GAAP gross profit $ 569.1 $ 469.8 Business transition and related costs (2) 3.5 1.1 Intellectual property litigation costs (3) 25.2 21.3 GAAP operating income $ 101.1 $ 47.2 Adjustments related to taxes (4) (57.3) ...

Exhibit 99.1 Dexcom Reports First Quarter 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-April 25, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: • Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. • U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1 basis, ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about DexCom (DXCM) .DexCom currently has an average brokerage recommen ...